
Agios Pharm
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $26.775
- Today's High:
- $27.47
- Open Price:
- $26.94
- 52W Low:
- $16.75
- 52W High:
- $34.76
- Prev. Close:
- $26.87
- Volume:
- 242648
Company Statistics
- Market Cap.:
- $1.30 billion
- Book Value:
- 20
- Revenue TTM:
- $14.24 million
- Operating Margin TTM:
- -2732.07%
- Gross Profit TTM:
- $12.54 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -18.17%
- Return on Equity TTM:
- -19.38%
Company Profile
Agios Pharm had its IPO on 2013-07-24 under the ticker symbol AGIO.
The company operates in the Healthcare sector and Biotechnology industry. Agios Pharm has a staff strength of 389 employees.
Stock update
Shares of Agios Pharm opened at $26.94 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $26.78 - $27.47, and closed at $27.11.
This is a +0.89% increase from the previous day's closing price.
A total volume of 242,648 shares were traded at the close of the day’s session.
In the last one week, shares of Agios Pharm have slipped by -3.76%.
Agios Pharm's Key Ratios
Agios Pharm has a market cap of $1.30 billion, indicating a price to book ratio of 1.623 and a price to sales ratio of 164.392.
In the last 12-months Agios Pharm’s revenue was $14.24 million with a gross profit of $12.54 million and an EBITDA of $-380483008. The EBITDA ratio measures Agios Pharm's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Agios Pharm’s operating margin was -2732.07% while its return on assets stood at -18.17% with a return of equity of -19.38%.
In Q4, Agios Pharm’s quarterly earnings growth was a positive 0% while revenue growth was a positive 24.3%.
Agios Pharm’s PE and PEG Ratio
- Forward PE
- 2.4655
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-4.04 per share while it has a forward price to earnings multiple of 2.4655 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Agios Pharm’s profitability.
Agios Pharm stock is trading at a EV to sales ratio of 107.3145 and a EV to EBITDA ratio of -2.7625. Its price to sales ratio in the trailing 12-months stood at 164.392.
Agios Pharm stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.24 billion
- Total Liabilities
- $62.63 million
- Operating Cash Flow
- $82.95 million
- Capital Expenditure
- $113000
- Dividend Payout Ratio
- 0%
Agios Pharm ended 2025 with $1.24 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.24 billion while shareholder equity stood at $1.10 billion.
Agios Pharm ended 2025 with $0 in deferred long-term liabilities, $62.63 million in other current liabilities, 71000.00 in common stock, $-470561000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $139.26 million and cash and short-term investments were $783.12 million. The company’s total short-term debt was $13,663,000 while long-term debt stood at $0.
Agios Pharm’s total current assets stands at $832.77 million while long-term investments were $313.87 million and short-term investments were $643.86 million. Its net receivables were $2.21 million compared to accounts payable of $18.62 million and inventory worth $8.49 million.
In 2025, Agios Pharm's operating cash flow was $82.95 million while its capital expenditure stood at $113000.
Comparatively, Agios Pharm paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $27.11
- 52-Week High
- $34.76
- 52-Week Low
- $16.75
- Analyst Target Price
- $37.8
Agios Pharm stock is currently trading at $27.11 per share. It touched a 52-week high of $34.76 and a 52-week low of $34.76. Analysts tracking the stock have a 12-month average target price of $37.8.
Its 50-day moving average was $26.78 and 200-day moving average was $26.39 The short ratio stood at 10.99 indicating a short percent outstanding of 0%.
Around 135% of the company’s stock are held by insiders while 10776.4% are held by institutions.
Frequently Asked Questions About Agios Pharm
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.